Paliperidone “Approvable” Puts Pressure On J&J Evergreening Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
While not unexpected, the regulatory delay means the company will have less time to transition patients to the Risperdal follow-on.
You may also be interested in...
J&J's Invega Will Launch In January As Follow-On To Risperdal
Paliperidone is the first atypical antipsychotic to be approved since 2003.
J&J's Invega Will Launch In January As Follow-On To Risperdal
Paliperidone is the first atypical antipsychotic to be approved since 2003.
J&J's Antipsychotic Franchise May Be "Invega"rated On Dec. 20
Risperdal follow-on's trade name is revealed; paliperidone will get a short re-review from FDA, company says.